THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biotechnology company developing Tcelna®, a novel T-cell immunotherapy for the treatment of secondary progressive multiple sclerosis (SPMS), today announced that the Company will report financial results for the three months ended June 30, 2014 after the close of trading on Thursday, August 14th. The Company will also conduct a conference call and webcast to discuss financial results and provide a corporate update at 5:00 P.M. EDT on Thursday, August 14th.
Help employers find you! Check out all the jobs and post your resume.
